Nutrition Journal (Jun 2022)

Intermittent fasting two days versus one day per week, matched for total energy intake and expenditure, increases weight loss in overweight/obese men and women

  • Paul J. Arciero,
  • Karen M. Arciero,
  • Michelle Poe,
  • Alex E. Mohr,
  • Stephen J. Ives,
  • Autumn Arciero,
  • Molly Boyce,
  • Jin Zhang,
  • Melissa Haas,
  • Emma Valdez,
  • Delaney Corbet,
  • Kaitlyn Judd,
  • Annika Smith,
  • Olivia Furlong,
  • Marley Wahler,
  • Eric Gumpricht

DOI
https://doi.org/10.1186/s12937-022-00790-0
Journal volume & issue
Vol. 21, no. 1
pp. 1 – 13

Abstract

Read online

Abstract Background Intermittent fasting (IF), consisting of either a one-day (IF1) or two consecutive days (IF2) per week, is commonly used for optimal body weight loss. Our laboratory has previously shown an IF1 diet combined with 6d/week of protein pacing (P; 4–5 meals/day evenly spaced, ~ 30% protein/day) significantly enhances weight loss, body composition, and cardiometabolic health in obese men and women. Whether an IF1-P or IF2-P, matched for weekly energy intake (EI) and expenditure (EE), is superior for weight loss, body composition, and cardiometabolic health is unknown. Methods This randomized control study directly compared an IF1-P (n = 10) versus an IF2-P (n = 10) diet on weight loss and body composition, cardiovascular (blood pressure and lipids), hormone, and hunger responses in 20 overweight men and women during a 4-week weight loss period. Participants received weekly dietary counseling and monitoring of compliance from a registered dietitian. All outcome variables were assessed pre (week 0) and post (week 5). Results Both groups significantly reduced body weight, waist circumference, percent body fat, fat mass, hunger, blood pressure, lipids, glucose, and increased percent fat-free mass (p 0.10). Conclusions These findings support short-term IF1-P and IF2-P to optimize weight loss and improve body composition, cardiometabolic health, and hunger management, with IF2-P providing enhanced benefits in overweight women and men. Trial registration This trial was registered March 03, 2020 at www.clinicaltrials.gov as NCT04327141 .

Keywords